TY - JOUR
T1 - Prognosis of medullary breast cancer
T2 - Analysis of 13 International Breast Cancer Study Group (IBCSG) trials
AU - Huober, J.
AU - Gelber, S.
AU - Goldhirsch, A.
AU - Coates, A. S.
AU - Viale, G.
AU - öhlschlegel, C.
AU - Price, K. N.
AU - Gelber, R. D.
AU - Regan, M. M.
AU - Thürlimann, B.
PY - 2012/11
Y1 - 2012/11
N2 - Background: To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors. Methods: Among 12 409 patients, 127 were recorded as invasive medullary tumors and 8096 invasive ductal tumors. Medullary and ductal invasive tumors were compared with regard to stage, age at diagnosis, grade, hormone receptor status, peritumoral vascular invasion, and local and systemic treatment. Pattern of relapse, distant recurrence-free interval (DRFI), and overall survival (OS) were determined for both histological groups. Two cohorts were investigated: a full cohort including the pathologist-determined medullary histology without regard to any other tumor features and a cohort restricted to patients with ER-negative grade 3 tumors. Results: Fourteen-year DRFI and OS percents for medullary tumors (n = 127) and invasive ductal tumors (n = 8096) of the full cohort were 76% and 64% [hazard ratio (HR) 0.52, P = 0.0005] and 66% and 57% (HR = 0.75, P = 0.03), respectively. For the restricted cohort, 14-year DRFI and OS percents for the medullary (n = 47) and invasive ductal tumors (n = 1407) were 89% and 63% (HR 0.24, P = 0.002) and 74% and 54% (HR = 0.55, P = 0.01), respectively. Competing risk analysis for DRFI favored medullary tumors (HR medullary/ductal = 0.32; 95% confidence interval = 0.13-0.78, P = 0.01). Conclusion: Medullary tumors have a favorable prognosis compared with invasive ductal tumors.
AB - Background: To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors. Methods: Among 12 409 patients, 127 were recorded as invasive medullary tumors and 8096 invasive ductal tumors. Medullary and ductal invasive tumors were compared with regard to stage, age at diagnosis, grade, hormone receptor status, peritumoral vascular invasion, and local and systemic treatment. Pattern of relapse, distant recurrence-free interval (DRFI), and overall survival (OS) were determined for both histological groups. Two cohorts were investigated: a full cohort including the pathologist-determined medullary histology without regard to any other tumor features and a cohort restricted to patients with ER-negative grade 3 tumors. Results: Fourteen-year DRFI and OS percents for medullary tumors (n = 127) and invasive ductal tumors (n = 8096) of the full cohort were 76% and 64% [hazard ratio (HR) 0.52, P = 0.0005] and 66% and 57% (HR = 0.75, P = 0.03), respectively. For the restricted cohort, 14-year DRFI and OS percents for the medullary (n = 47) and invasive ductal tumors (n = 1407) were 89% and 63% (HR 0.24, P = 0.002) and 74% and 54% (HR = 0.55, P = 0.01), respectively. Competing risk analysis for DRFI favored medullary tumors (HR medullary/ductal = 0.32; 95% confidence interval = 0.13-0.78, P = 0.01). Conclusion: Medullary tumors have a favorable prognosis compared with invasive ductal tumors.
KW - Breast cancer
KW - Histology
KW - Invasive ductal
KW - Medullary
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=84868116683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868116683&partnerID=8YFLogxK
U2 - 10.1093/annonc/mds105
DO - 10.1093/annonc/mds105
M3 - Article
C2 - 22707751
AN - SCOPUS:84868116683
VL - 23
SP - 2843
EP - 2851
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 11
M1 - mds105
ER -